160313-69-9

Usage

Chemical Properties

Pale red liquid or solid

InChI:InChI=1/C10H11BrO2/c1-3-13-10(12)8-4-5-9(11)7(2)6-8/h4-6H,3H2,1-2H3

Upstream product

• 64-17-5 ethanol 
• 7697-28-1 4-bromo-3-methylbenzoic acid 

Downstream Products

• 160313-46-2 2-<(2'-bromo-5'-ethoxycarbonyl)phenyl>-1,3-dioxolane 
• 160313-47-3 2-<<2'-bromo-5'-(2''-hydroxyethoxy)carbonyl>phenyl>-1,3-dioxolane 
• 347852-72-6 ethyl 4-bromo-3-(bromomethyl)benzoate 
• 149104-89-2 4-bromo-3-methylbenzylalcohol 
• 1175527-52-2 2-(4-Bromo-3-methyl-phenyl)-propan-2-ol 
• 1186638-06-1 ethyl 3-methyl-4-((triethylsilyl)ethynyl)benzoate 
• 1186635-80-2 (4-(2-(5-amino-8-methylbenzo[f][1,7]naphthyridin-2-yl)ethyl)-3-methylphenyl)methanol 
• 1186638-00-5 4-(2-(5-amino-8-methylbenzo[f][1,7]naphthyridin-2-yl)ethyl)-3-methylbenzaldehyde 
• 1186635-68-6 (E)-ethyl 3-(4-(2-(5-amino-8-methylbenzo[f][1,7]naphthyridin-2-yl)ethyl)-3-methylphenyl)acrylate 
• 1186638-01-6 diethyl 2-(4-(2-(5-amino-8-methylbenzo[f][1,7]naphthyridin-2-yl)ethyl)-3-methylbenzyl)malonate 
• 1186638-07-2 ethyl 4-ethynyl-3-methylbenzoate 
• 1186638-08-3 ethyl 4-((5-chloro-6-cyanopyridin-3-yl)ethynyl)-3-methylbenzoate 
• 1186638-09-4 ethyl 4-((5-amino-8-methylbenzo[f][1,7]naphthyridin-2-yl)ethynyl)-3-methylbenzoate 
• 1186635-77-7 ethyl 4-(2-(5-amino-8-methylbenzo[f][1,7]naphthyridin-2-yl)ethyl)-3-methylbenzoate 

Relevant academic research and scientific papers

Preparation method and application of 3-methyl-4-formaldoxime ethyl benzoate

The invention relates to a preparation method of 3-methyl-4-formaldoxime ethyl benzoate. The method comprises the steps that S1, 4-bromo-3-methylbenzoic acid is dissolved into ethanol, an acylating chlorination reagent is added for conducting an reaction

A stable isotope-labeled diphenyl sulfonamide pharmaceutical preparation method

The invention discloses a preparation method of sparsenatan for stabilizing isotope labeling. According to the method, 3-methyl-4-bromobenzoic acid is used as a raw material, iodoethane for deuterium labeling serves as a deuterium labeling initiator, and

Homogenous suspension of immunopotentiating compounds and uses thereof

The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.

HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is -CR4=CR5.

NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE AT1 AND ETA RECEPTORS

The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously known agents. The invention also relates to the use of the above-mentioned compounds and combinations for the preparation of a medicament for treating hypertension of different kinds, alleviating organ damage of different kinds, treating or preventing diabetic nephropathy, treating endothelin and angiotensin mediated disorders, and treating prostate cancer.

CONDENSED PYRAZOLE DERIVATIVES, METHOD OF MANUFACTURING THE SAME, AND ANDROGEN INHIBITOR

This invention provides a condensed pyrazole derivative of the Formula (1): STR1 (where A denotes CH or N, R 0 and R 3 denote same or different, a hydrogen atom or a lower alkyl group, R 1 and R 2 denote same or different, a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a nitro group or a halogen atom, m denotes 1 or 2, and n denotes 1, 2 or 3, provided that, when n is 2, two R 2 may be connected to each other to form a lower alkylenedioxy group), or its pharmaceutically acceptable salt. This derivative or its salt is excellent in the effect of inhibiting the expression of action of androgen, thereby being excellent in therapeutical effect of benign prostatic hypertrophy, prostatic carcinoma, etc., and has a long lasting of efficacy and high oral absorption.

Synthesis of a Spheroidal Bis-porphyrin: a Ligand Designed to Accept Two Catalytic Metal Ions in an Isolated Environment

A spheroidal bis-porphyrin (dual capped quadruply cofacial dimeric tetraphenylporphyrin, 1), designed to be employed as a ligand for a class of catalysts that mimic the combined enzyme activities of superoxide dismutase and catalase, has been synthesized